March 2012
Volume 53, Issue 14
ARVO Annual Meeting Abstract  |   March 2012
Macular Pigment Response To Three Different Macular Carotenoid Interventions In Patients With Early Age-Related Macular Degeneration
Author Affiliations & Notes
  • John M. Nolan
    Macular Pigment Research Group, Waterford Institute of Technology, Waterford, Ireland
  • Sarah Sabour-Pickett
    Institute of Vision Research, Waterford, Ireland
  • Eithne Connolly
    Institute of Vision Research, Waterford, Ireland
  • Loughman James
    Optometry, Dublin Institute of Technology, Dublin, Ireland
  • Alan Howard
    Howard Foundation, Cambridge, United Kingdom
  • Stephen Beatty
    Institute of Eye Surgery, Waterford, Ireland
  • Footnotes
    Commercial Relationships  John M. Nolan, None; Sarah Sabour-Pickett, None; Eithne Connolly, None; Loughman James, None; Alan Howard, None; Stephen Beatty, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 3368. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      John M. Nolan, Sarah Sabour-Pickett, Eithne Connolly, Loughman James, Alan Howard, Stephen Beatty; Macular Pigment Response To Three Different Macular Carotenoid Interventions In Patients With Early Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2012;53(14):3368.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To investigate the impact of three different macular carotenoid interventions on macular pigment optical density (MPOD), in subjects with early age-related macular degeneration (AMD).

Methods: : Seventy-five subjects (75 study eyes) with early AMD were recruited into this single-blind, randomised clinical trial. Stereo fundus photographs were graded at the accredited reading centre at the University of Wisconsin, USA. AMD was defined as the presence of drusen and pigmentary changes. Of the 75 eyes, 9 were classified as having "atypical-AMD" (i.e. the presence of pigmentary changes only). Subjects were randomly assigned into one of the three intervention groups, as follows: Group 1 (n = 25): L = 20 mg/day, zeaxanthin (Z) = 2 mg/day; Group 2 (n = 28): meso-zeaxanthin (MZ) = 10 mg/day, L = 10 mg/day, Z = 2 mg/day; Group 3 (n = 22): MZ = 17 mg/day, L = 3 mg/day, Z = 2 mg/day. MPOD was measured using customised heterochromatic flicker photometry at four retinal eccentricities (0.25°, 0.5°, 1.0° and 1.75°) and visual function was assessed using a range of psychophysical tests. Study visits occurred at baseline, three, six and 12 months.

Results: : Twenty-eight (37%) of the subjects were male. Mean (±sd) values at baseline were, as follows: age (years) = 67.2 (±8.4); MPOD (at 0.25°) = 0.47 (±0.23); corrected distance visual acuity (CDVA) = 97.4 (±7.6) (circa. LogMAR: 0.05). Positive and statistically significant relationships between MPOD (at 0.25°) and visual function at baseline included: CDVA, letter contrast sensitivity, measures of grating contrast sensitivity and glare disability (r = 0.239-0.357; p<0.05, for all). Longitudinal analysis demonstrated a statistically significant increase in MPOD at 0.25° in Group 2 only (p=0.003); at 0.5° in Groups 1 and 2 (p = 0.043 and p = 0.001, respectively); at 1.0° in Group 2 only (p = 0.012); at 1.75° in Groups 1 and 2 (p = 0.046 and p = 0.002, respectively).

Conclusions: : Cross-sectional analysis shows that MPOD correlates positively with important measures of visual function, in subjects with early AMD. In addition, we found that enrichment of MP across its spatial profile can be best achieved following supplementation with all three macular carotenoids (L, MZ and Z), for subjects with the disease. The morphological and functional implications of these findings merit investigation, and will follow.

Clinical Trial: :, ISRCTN81595685

Keywords: macular pigment • carotenoids/carotenoid binding proteins 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.